CRISPR/Cas9

News

Intellia’s president and chief executive John Leonard

Intellia files CRISPR drug after historic phase 3 readout

Intellia has reported the first-ever phase 3 results with an in vivo gene-editing therapy, CRISPR-based lonvo-z for hereditary angioedema.

News

KJ's parents, Kyle and Nicole, and his three siblings

World first as infant gets personalised CRISPR therapy

In a medical breakthrough, a child diagnosed with a rare genetic disorder has received a bespoke CRISPR gene editing therapy to correct the mutation.

News

Sickle cell gene therapy Casgevy finally cleared for NHS use

Vertex's gene-editing therapy for sickle cell disease, Casgevy, has been given the nod for use by the NHS in England after an earlier rejection.

News

Editas axes two-thirds of its staff, including its CMO

Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.

News

After a no in sickle cell, NICE OKs Casgevy for thalassaemia

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it dow

R&D

Opportunity costs of gene therapies. Where do we go from her...

Over 30 gene therapies have received regulatory approval.

Intellia files CRISPR drug after historic phase 3 readout

World first as infant gets personalised CRISPR therapy

Sickle cell gene therapy Casgevy finally cleared for NHS use

Editas axes two-thirds of its staff, including its CMO

After a no in sickle cell, NICE OKs Casgevy for thalassaemia

Opportunity costs of gene therapies. Where do we go from her...

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

CRISPR/Cas9

Editor's Picks